Our History

We have come a long way

Yes we have come a long way since we started in 1985. Ever since the beginning we have been a partner of choice for all the largest entities in the generic pharmaceutical industry, punching far above our weight every single day. We are very proud of our humble and small beginning, and at the same time we look forward to the future and what it brings.

Medis wins Company of the Year – EMEA Award

  • Medis wins Company of the Year – EMEA award at the Global Generics & Biosmilars Awards 2017
  • Significantly improved market access in Ukraine, Central America and Greece.

Market scope:

  • 167 product/market launches of more than 1000 SKUs
  • Top 3 products were Pregabalin, Atorvastatin and Nebivolol

Medis and Teva Industrial business combined under the Medis name

  • Teva Pharmaceuticals Ltd acquires Actavis Generics, including Medis
  • New office in Madrid

Market scope

  • Sold 242 products/INN to 313 clients in 74 markets

30th Anniversary of Medis

  • Opens offices in Dubai, UAE, in Warsaw, Poland, and re-launching presence in Brazil
  • Medis wins ‘Business Development of the Year’ at Global Generics & Biosimilar Awards

Key launch

  • Pregabalin, where Medis’ customers were first to launch the product in both the UK and Germany

1 billion units sold in France in a single year

  • New office in Paris, France. Office in Como, Italy opens. Over 100 employees for first time

Key launches

  • Nicotine Replacement Therapy (NRT) – 27 million units
  • Budesonide solution – 15.4 million units
  • Levodopa/Carbidopa/Entacapone – 11.3 million units
  • Rosuvastatin – 22 million units

Market scope

  • 78 markets sold to from beginning. 61 markets sold to in the year. Sold to 266 clients. Total number of products is 238.

Annual sales reach over $300 m.

  • Spirit was renamed Medis Pharma PTY.
  • Medis reaches SOX Compliant status.

Key launch

  • Telmisartan HCT – 37 million units.

Market scope

  • 73 markets sold to from beginning. 58 markets sold to in the year. Sold to 258 clients.

Medis and Specifar combine businesses

Key launches

  • Riluzole – 3.8 million units.
  • Esomeprazole – 13 million units.

Market scope

  • 69 markets sold to from beginning. 52 markets sold to in the year. Sold to 266 clients.

Medis moves to new HQ in Iceland

Key launch

  • Repaglinide – 81 million units.

Market scope

  • 67 markets sold to from beginning. 49 markets sold to in the year.
  • Sold to 248 Clients/Customers this year.

Annual Revenues Over €200M

Medis portfolio established. Portfolio reaches 100 products. Local presence in Italy and Poland.

Key launch

  • Docetaxel solution (Novel) – 0.04 million units.

Market scope

  • 62 markets sold to from beginning. 48 markets sold to in the year. Sold to 238 clients.
  • Annual revenues over €200 m.

Spanish office established in Barcelona

Local presence in Russia/CIS

Key launches

  • Atorvastatin Magnesium – 70.8 million, launch in Spain.
  • Clopidrogel Besylate – 64 million units.
  • Gemcitabine freeze dried – 0.3 million units.
  • Pantoprazole – 50 million unit.

Market scope

  • 60 markets sold to from beginning. 46 markets sold to in the year. Sold to 209 clients.

Total number of sold units reaches 3 billion

Gudbjorg Edda leaves Medis to take on a senior management role for Actavis. Valur Ragnarsson new CEO.

Key launches

  • Olanzapine orodispersible – 4.8 million units.
  • Nebivolol – 19 million unit.

Market scope

  • Sold to 178 clients in 43 markets this year.

French office opens

Local presence in Dubai and Singapore.

Key launches

  • AOK in Germany.
  • Olanzapine -12 million units.

Market scope

  • Sold to 161 clients in 44 markets this year.

First launch from India: FINASTERIDE

Key launch

  • Sumatriptan – 1.8 million units.

Market scope

  • 47 markets sold to in the year. Sold to 144 clients.

Ramipril sold in 17 countries

  • Actavis Acquired Alpharma, Medis customer.

Key launches

  • Glimepride – 129 million units.
  • Lamotrigine dispersible – 27 million units.

Market scope

  • Sold to 110 clients in 39 markets this year.

Dedicated launch coordination department established

Key launches

  • Ramipril Launch – 223 million units; UK / DE / DK (9 countries in total).
  • Lis HCT – 86 million units, launched from Malta.
  • Quinapril HCT – 28 million units.

Market scope

  • 36 markets sold to. Sold to 79 clients.

Annual revenues over €100 m.

  • Opening of Malta factory with Medis customer event.

Key launch

  • Fluconazole – 1.5 million units.

Medis Germany founded

Total number of products is 20.

Key launch

  • Citalopram – 50 million units.

Market scope

  • 20 Markets sold to in the year. Sold to 54 Clients.

Launch of Lisinopril tablets

  • Medis – Isle of Man established.

Key launches

  • Ciprofloxacin – 41 million units.
  • Lisinopril – 286 million units.
  • Loratadine – 45 million units.

Annual sales of €20 m.

First stand at CPhI.

Captopril launch in Germany

Medis founded.

Locations

worldwide operations and facilities

ACBF5E14-A57C-4383-BDFF-04EA66B1D3D8 Created with sketchtool.